Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: A review of pathophysiology, safety, and efficacy

American Journal of Clinical Dermatology

Volumn 10, Issue 2, 2009, Pages 103-118

  Cook, Bethany A ^a   Warshaw, Erin M ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCITONIN GENE RELATED PEPTIDE; CICLOPIROX; CLOBETASOL; COAL TAR; CORTICOSTEROID DERIVATIVE; CYTOKINE; DESONIDE; FK 506 BINDING PROTEIN; FLUCONAZOLE; HYDROCORTISONE; ITRACONAZOLE; KERATOLYTIC AGENT; KETOCONAZOLE; MINOCYCLINE; PIMECROLIMUS; PRAMICONAZOLE; PYRITHIONE ZINC; SALICYLIC ACID; SELENIUM SULFIDE; SUBSTANCE P; SUCCINATE LITHIUM; TACROLIMUS; TEA TREE OIL; TERBINAFINE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

BURNING SENSATION; CARCINOGENICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IRRITANT DERMATITIS; LIVER TOXICITY; MALASSEZIA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PERIORAL DERMATITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ATROPHY; STRIA; TACHYPHYLAXIS; TELANGIECTASIA; ULTRAVIOLET B RADIATION;

ADMINISTRATION, CUTANEOUS; CALCINEURIN; DERMATITIS, SEBORRHEIC; DERMATOLOGIC AGENTS; HUMANS; PATIENT SATISFACTION; RECURRENCE; TACROLIMUS; TREATMENT OUTCOME;

EID: 62449225087     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200910020-00003     Document Type: Review

References (93)

1. Peyri J, Lleonart M. Grupo espanol del Estudio SEBDERM. Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis. Actas Dermosifiliogr 2007 Sep; 98 (7): 476-82
2. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology 2004; 208 (2): 89-93
3. de Moraes AP, Arruda E, Vitoriano MAV, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venereol 2007 May; 21 (5): 596-601
4. Fischer M, Gemende I, Marsch WC, et al. Skin function and skin disorders in Parkinsons disease. J Neural Transm 2001; 108 (2): 205-13
5. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004 Jan; 18 (1): 13-26
6. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Derm 2006 Jun; 54 (6): 1083-8
7. Plewig G, Jansen T. Seborrheic dermatitis. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 1482-9
8. Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatol 1989 Apr; 6 (2): 80-4
9. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004 Nov; 51 (5): 785-98
10. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006 Jul 1; 74 (1): 125-30
11. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh) 1991; 167: 1-36
12. Harding C, Moore A, Rogers J, et al. Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function. Arch Dermatol Res 2002 Jul; 294 (5): 221-30
13. Erchiga VC, Florencio VD. Malassezia species in skin diseases. Curr Opin Infect Dis 2002; 15: 133-42
14. Piérard GE, Ausma J, Henry F, et al. A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Dermatology 2007; 214 (2): 162-9
15. Tajima M, Sugita T, Nishikawa A, et al. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol 2008 Feb; 128 (2): 345-51
16. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139: 254-63
17. Wikler JR, Nieboer C, Willemze R. Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. J Am Acad Dermatol 1992 Jul; 27 (1): 37-9
18. Faergemann J, Bergbrant IM, Dohse M, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001 Mar; 144 (3): 549-56
19. Kahlke B, Brasch J, Christophers E, et al. Dermatophytes contain a novel lipid-like leukocyte activator. J Invest Dermatol 1996 Jul; 107 (1): 108-12
20. Mayser P, Haze P, Papavassilis C, et al. Differentiation of Malassezia species: selectivity of Cremophor EL, castor oil and ricinoleic acid for M. furfur. Br J Dermatol 1997 Aug; 137 (2): 208-13
21. Xu J, Saunders C, Hu P. Dandruff-associated Malassezia genomes reveal convergent and divergent virulence traits shared with plant and human fungal pathogens. Proc Natl Acad Sci U S A 2007 Nov; 104 (47): 18730-5
22. Elewski B, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol 2007 Oct; 6 (10): 1001-8
23. Ratnavel RC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat 2007; 18 (2): 88-96
24. Roques C, Brousse S, Panizzutti C. In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains. Mycopathologia 2006 Dec; 162 (6): 395-400
25. Vena GA, Micali G, Santoianni P, et al. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. Int J Immunopathol Pharmacol 2005 Oct-Dec; 18 (4): 745-53
26. Cömert A, Bekiroglu N, Gürbüz O, et al. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: a placebo-controlled study. Am J Clin Dermatol 2007; 8 (4): 235-8
27. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br JDermatol 2003 Jan; 148 (1): 128-33
28. Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006 Jan; 54 (1): 1-15
29. Gilbertson EO, Spellman MC, Piacquadio DJ, et al. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998 Feb; 38 (2 Pt 2): 318-21
30. Rapaport MJ, Lebwohl M. Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome. Clin Dermatol 2003 May-Jun; 21 (3): 201-14
31. Piérard-Franchimont C, Piérard GE. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology 2002; 204 (4): 344-7
32. Reygagne P, Poncet M, Sidou F, et al. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis 2007 May; 79 (5): 397-403
33. Nenoff P, Haustein UF, Fiedler A. The antifungal activity of a coal tar gel on Malassezia furfur in vitro. Dermatology 1995; 191 (4): 311-4
34. Nenoff P, Haustein UF, Munzberger C. In vitro activity of lithium succinate against Malassezia furfur. Dermatology 1995; 190 (1): 48-50
35. Langtry JA, Rowland Payne CM, Staughton RC, et al. Topical lithium succinate ointment (Efalith) in the treatment of AIDS-related seborrhoeic dermatitis. Clin Exp Dermatol 1997 Sep; 22 (5): 216-9
36. Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993 Dec; 29 (6): 1008-12
37. Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol 1996; 9 (6): 388-94
38. Satchell AC, Saurajen A, Bell C, et al. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol 2002 Dec; 47 (6): 852-5
39. Pirkhammer D, Seeber A, Honigsmann H, et al. Narrow-band ultraviolet B(TL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000 Nov; 143 (5): 964-8
40. Mrowietz U. Ascomycin macrolactams. J Cutan Med Surg 2001; 5: 22-5
41. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Exp Opin Invest Drugs 2000 Jan; 9 (1): 69-77
42. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999 Aug; 141 (2): 264-73
43. Graham-Brown RA, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 2003 May; 57 (4): 319-27
44. Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus: an antiinflammatory drug targeting the skin. Exp Dermatol 2004 Dec; 13 (12): 721-30
45. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002 Feb; 46 (2): 228-41
46. Panhans-Gross A, Novak N, Kraft S, et al. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001 Feb; 107 (2): 345-52
47. Sugita T, Tajima M, Ito T, et al. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 2005 Jun; 43 (6): 2824-9
48. Maesaki S, Marichal P, Hossain MA, et al. Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J Antimicrob Chemother 1998 Dec; 42 (6): 747-53
49. Xhauflaire-Uhoda E, Thirion L, Pierard-Franchimont C, et al. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology 2007; 214 (4): 328-32
50. Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007; 57 (2): 257-64
51. Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142: 1066-7
52. Rigopoulos D, Ioannides D, Kalogeromitros D, et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis: a randomized open-label clinical trial. Br J Dermatol 2004; 151: 1071-5
53. Rallis E, Nasiopoulou A, Kouskoukis C, et al. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 2004; 30: 191-5
54. Cunha PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol 2006; 86 (1): 69-70
55. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 2003; 9: 13
56. Crutchfield III CE. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 2002; 70: 207-8
57. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145-7
58. Braza TJ, DiCarlo JB, Soon SL, et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003; 148: 1242-4
59. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13
60. Ständer S, Ständer H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release andmast cell degranulation in murine skin. Br J Dermatol 2007; 156: 1020-6
61. Milingou M, Antille C, Sorg O, et al. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 2004 Dec; 140 (12): 1542-4
62. Ehst BD, Warshaw EM. Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Arch Dermatol 2004 Aug; 140 (8): 1014-5
63. Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream [letter]. Arch Dermatol 2005; 141 (9): 1168
64. Lübbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology 2003; 207: 204-5
65. Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 2004 Apr; 140 (4): 457-60
66. Billich A, Aschauer H, Aszodi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004 Jan 9; 269 (1): 29-35
67. Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001 Nov; 45 (5): 736-43
68. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000 Aug; 136 (8): 999-1006
69. Van Leent EJ, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204 (1): 63-8
70. Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis: a multicenter, 3-week, open-label study. Pediatr Dermatol 2005 Sep-Oct; 22 (5): 465-71
71. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 Nov; 88 (11): 969-73
72. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 781-7
73. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006 May; 54 (5): 818-23
74. FDA. Pharmacokinetics/toxicokinetics: brief summary, 2005: 1-18 [online]. Available from URL: http://www.fda.gov/fdac/departs/2006/206-upd.html#eczema [Accessed 2008 Nov 24]
75. Patel TS, Greer SC, Skinner RB. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol 2007; 8 (4): 189-94
76. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211 (2): 174-87
77. Drug Regulatory Affairs. Elidel (pimecrolimus) cream 1%. NDA 21-302, 2005 [online]. Available from URL: http://www/fda/gov/ohrms/dockets/ac/05/slides/ 2005-4089s2-01-06-Hill.ppt [Accessed 2007 Oct 15]
78. FDA. Protopic (tacrolimus) ointment. Center for Drug Evaluation and Research application number 50777, 2005: 1-51 [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2000/50777-protopic.htm [Accessed 2007 Oct 15]
79. FDA/Center for Drug Evaluation and Research. Elidel (pimecrolimus) cream [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2001/21-302 [Accessed 2007 Oct 15]
80. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 Jul; 110 (1 Pt 1): e2
81. Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005 Feb; 52 (2): 240-6
82. Fleischer AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Dermatolog Treat 2007; 18 (3): 151-7
83. Tran C, Lubbe J, Sorg O. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005; 211 (4): 341-7
84. Paller AS, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810-22
85. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515-25
86. Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 1999; 288: 653-9
87. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-41
88. Novartis, Fujisawa. FDA briefing statements. Pediatric Advisory Committee meeting of the US FDA; 2005 Feb 15; Washington, DC
89. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern. Br J Dermatol 2005; 153: 701-5
90. Soter NA, Fleischer AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II. Safety. J Am Acad Dermatol 2001; 44: S39-46
91. Abramovits W, Boguniewicz M, Paller AS, et al. The economics of topical immunomodulators for the treatment of atopic dermatitis. Pharmacoeconomics 2005; 23: 543-66
92. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003 Apr; 48 (4): 553-63
93. Ellis CN, Kahler KH, Grueger J, et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol 2006; 7 (2): 133-9